Previous 10 | Next 10 |
STAMFORD, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today an...
With so many companies struggling in the cannabis market , it's easy to predict doom and gloom for the whole industry, but that's far from the case. It's just an emerging market with a ridiculous upside, and some companies are bound to struggle. It may be inevitable that many in the sector won...
Based the recommendation from the independent Data Monitoring Committee, Cara Therapeutics (NASDAQ: CARA ) will increase the size of its Phase 2 dose-ranging clinical trial, KARE , evaluating oral Korsuva (CR845/difelikefalin) for the treatment of moderate-to-severe pruritis (itchy skin) ...
- Patient enrollment increased approximately 28% to maintain > 80% statistical power for primary endpoint and key registration endpoint of > 4-point improvement responder analysis - - Full trial enrollment expected in fourth quarter of 2020 - STAMFORD, Conn., June...
STAMFORD, Conn., May 27, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, toda...
The following slide deck was published by Cara Therapeutics, Inc. in conjunction with their 2020 Q1 earnings Read more ...
Image source: The Motley Fool. Cara Therapeutics Inc (NASDAQ: CARA) Q1 2020 Earnings Call May 11, 2020 , 4:30 p.m. ET Operator Continue reading
Cara Therapeutics, Inc. (CARA) Q1 2020 Earnings Conference Call May 11, 2020 4:30 PM ET Company Participants Jack Hildick-Smith - Stern Investor Relations Derek Chalmers - President & Chief Executive Officer Rick Makara - Vice President & Head of Accounting Conference ...
Cara Therapeutics (NASDAQ: CARA ): Q1 GAAP EPS of -$0.62 beats by $0.01 . Revenue of $8.1M (+84.1% Y/Y) beats by $3.39M . Press Release More news on: Cara Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,
STAMFORD, Conn., May 11, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today ann...
News, Short Squeeze, Breakout and More Instantly...
Cara Therapeutics Inc. Company Name:
CARA Stock Symbol:
NASDAQ Market:
Cara Therapeutics Inc. Website:
– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Onset of action seen at Week 1 and sustained through Week 8 – – Statistical significance achieve...
KORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation Kapruvia ® (difelikefalin) approved by European Commission for the treatment of moderate-to-severe pruritus associated with chronic kidney disease...
STAMFORD, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President an...